RUTH.AQSE

Rutherford Health Plc
Rutherford Health - Directorate Change
9th December 2021, 12:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 1469V
Rutherford Health PLC
09 December 2021
 

Rutherford Health Plc

Directorate Change

 

 

9 December 2021: Rutherford Health plc (AQSE: RUTH, the "Group"), a healthcare group committed to providing innovative cancer care of the highest quality, announces the appointment of Dr Mark Jackson as the Non-executive Chairman of the Group with effect from 7 December 2021 and a Non-executive Director of the Company with effect from 6 December 2021.  Mark worked for many years as a GP practice lead before founding and growing his own successful company. He has also served on the boards of a number of well-known companies in the health and care sectors, including several years as the Chairman of Exemplar Health Care, Deputy Chairman of Allied Healthcare as well as Non-Executive Director at UME Group. Rupert Lowe has completed his term as Chairman and has agreed to remain as a Non-Executive Director and support the Company's new Chairman.  

 

Having now built the business, Mike Moran will be stepping down as Chief Executive Officer (CEO).

The company would like to thank Mike for his hard work in building the centres and establishing operational capability.

 

The intention is for a new CEO to be appointed in early 2022.  An experienced interim, Sean Sullivan, has been appointed as a Chief Restructuring Officer to bridge the intervening period and assist in consolidating our position.  Also in the interim, the Company intends to appoint a strategic advisory firm to support its development of a growth orientated business plan going forward.

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

 

For more information, please contact:

 

Rutherford Health plc

Tel: +44 (0) 16 3381 0661


Marcus King, Finance Director

Investors@therutherford.com

 

 

Grant Thornton (Corporate Adviser)

Tel: +44 (0) 20 7383 5100

Colin Aaronson/ George Grainger

 

 

 

Instinctif Partners

Tel: +44 207 457 2020

Melanie Toyne-Sewell / Jeremy Durrant / Rozi Morris /
 

Rutherford@Instinctif.com

 

 

Media House International

Tel: 07788 414 856 or 0207 710 0020

Ramsay Smith

ramsay@mediahouse.co.uk

 

 

 

About Rutherford Health plc

Rutherford Health plc is a leading UK provider of innovative cancer care. Operating a network of four state-of-the-art centres in Wales, Reading, Northumberland and Liverpool, Rutherford Health offers a comprehensive range of the latest technology in cancer treatments, and is the only independent provider of proton beam therapy ("PBT") in the UK. The Company also provides conventional radiotherapy, chemotherapy, immunotherapy, imaging and wellbeing services.

The Group is listed on the Apex segment of the AQSE Growth Market under the symbol: RUTH. For more information, visit the Group's website:  www.rutherfordhealth.com .

 

The following disclosures are made pursuant Rule 4.9 of the AQSE Growth Market Apex Rulebook.

 

Mark Bentley Jackson is or has been a director of the following companies in the previous five years:

 

Current directorships and partnerships

Former directorships and/or partnerships (within the last five years)

-     Astonbrook Care Limited

-     Astonbrook Care Holdings Limited

-     Astonbrook Care Newco 1 Limited

-     Astonbrook Care Newco 2 Limited

-     Astonbrook Care Newco 3 Limited

-     Astonbrook Care Newco 4 Limited

-     Bentley Consulting Limited

-     Medigold Health Consultancy Limited Moorlands (Strensall) Limited

-     Birchlands (Haxby) Limited

-     Byron Lodge (West Melton) Limited

-     Castle Meadows (Dudley) Limited

-     Creo Medical Limited

-     CX Topco Limited

-     Dunniwood Lodge (Doncaster) Limited

-     Exemplar Health Care Services Limited

-     Glasgow Healthcare Facilities Limited

-     Glasgow Healthcare Facilities (Holdings) Limited

-     Headingley Care Centre (Edlington) Limited

-     Key Care Limited Mahogany House (Newtown) Limited

-     National Deposit Friendly Society Limited (trading as National Friendly)

-     Nethercrest Care Centre (Dudley) Limited

-     Pondsmead (Shepton Mallet) Limited

-     Rangeford Care Limited

-     Rangeford Holdings Limited (formerly known as Rangeford Limited)

-     Sandhall Park (Goole) Limited

-     The Abbeys (Rawmarsh) Limited

-     The Poplars (Thornaby) Limited

-     The Willows (Codsall) Limited

-     United Medical Enterprises Group (UK) (also known as UME Group)

-     Valley Park Care Centre (Wombwell) Limited

-     Warren Park (Chapeltown) Limited

-     White Ash Brook (Accrington) Limited


One of the companies of which Dr Jackson is currently a director, Astonbrook Care Holdings Limited is currently in administration and another, Astonbrook Care Limited, is in creditors voluntary liquidation. These processes, which have not yet been completed, are part of the winding up of the wider Astonbrook group.

 

There is no further information required to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Apex Rulebook.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXBBBDDRUGDGBC ]]>
TwitterFacebookLinkedIn